Current and future physiologically based pharmacokinetic (PBPK) modeling approaches to optimize pharmacotherapy in preterm neonates

References

• Allegaert K, van den Anker J. Neonatal drug therapy: the first frontier of therapeutics for children. Clin Pharmacol Ther. 2015;98(3):288–297.
   PubMed Web of Science ®Google Scholar
• van den Anker J, Allegaert K. Considerations for drug dosing in premature infants. J Clin Pharmacol. 2021;61(1):S141–S151.
   PubMedGoogle Scholar
• Krekels EHJ, van Hasselt JGC, van den Anker JN, et al. Evidence-based drug treatment for special patient populations through model-based approaches. Eur J Pharm Sci. 2017;109S:S22–S26.
   PubMedGoogle Scholar
• Allegaert K, Mian P, van den Anker JN. Developmental pharmacokinetics in neonates: maturational changes and beyond. Curr Pharm Des. 2017;23(38):5769–5778.
   PubMed Web of Science ®Google Scholar
• van Groen Bd, Nicolaï J, and Kuik AC, et al. Ontogeny of hepatic transporters and drug-metabolizing enzymes in humans and in nonclinical species. Pharmacol Rev. 2021;73(2):597–678.
   PubMed Web of Science ®Google Scholar
• Smits A, Annaert P, and Cavallaro G, et al. Current knowledge, challenges and innovations in developmental pharmacology: a combined conect4children expert group and European society for developmental, perinatal and paediatric pharmacology white paper. Br J Clin Pharmacol. 2021, https://doi.org/10.1111/bcp.14958.
   Google Scholar
• Grimstein M, Yang Y, Zhang X, et al. Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration’s office of clinical pharmacology. J Pharm Sci. 2019;108(1):21–25.
   PubMed Web of Science ®Google Scholar
• Allegaert K, van den Anker J. Dose-related adverse drug events in neonates: recognition and assessment. J Clin Pharmacol. 2021;61(1):S152–S160.
   PubMedGoogle Scholar
• Davis JM, Baer GR, McCune S, et al. Standardizing safety assessment and reporting for neonatal clinical trials. J Pediatr. 2020;219:243–249.e1.
   PubMedGoogle Scholar
• Wilbaux M, Kasser S, Gromann J, et al. Personalized weight change prediction in the first week of life. Clin Nutr. 2019;38(2):689–696.
   PubMedGoogle Scholar
• Chou FS, Yeh HW. Sex differences in postnatal weight gain trajectories of extremely preterm newborns. J Perinatol. 2021;41(8):1835–1844.
   PubMedGoogle Scholar
• Wang C, Allegaert K, Peeters MY, et al. The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults. Br J Clin Pharmacol. 2014;77(1):149–159.
   PubMed Web of Science ®Google Scholar
• van Rongen A, Krekels EH, Calvier EA, et al., An update on the use of allometric and other scaling methods to scale drug clearance: towards decision tables. Expert Opin Drug Metab Toxicol. 2022;18(2): 99–113.
   PubMedGoogle Scholar
• Mahmood I. Misconceptions and issues regarding allometric scaling during the drug development process. Expert Opin Drug Metab Toxicol. 2018;14(8):843–854.
   PubMed Web of Science ®Google Scholar
• Mahmood I, Tegenge MA. A comparative study between allometric scaling and physiologically based pharmacokinetic modeling for the prediction of drug clearance from neonates to adolescents. J Clin Pharmacol. 2019;59(2):189–197.
   PubMed Web of Science ®Google Scholar
• Bi Y, Liu J, Li L, et al. Role of model-informed drug development in pediatric drug development, regulatory evaluation and labeling. J Clin Pharmacol. 2019;59(1):S104–S111.
   PubMedGoogle Scholar
• Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48(1):303–332.
   PubMedGoogle Scholar
• Abduljalil K, Pan X, Pansari A, et al., A preterm physiologically based pharmacokinetic model. Part I: physiological parameters and model building. Clin Pharmacokinet. 59(4): 485–500. 2020.
   PubMed Web of Science ®Google Scholar
• Völler S, Flint RB, Simons SHP, et al. Comment on: “preterm physiologically based pharmacokinetic model, part I and part II.” Clin Pharmacokinet. 2021;60(5):677–679.
   PubMedGoogle Scholar
• Wu Y, Allegaert K, Flint RB, et al. Prediction of glomerular filtration rate maturation across preterm and term neonates and young infants using inulin as marker. AAPS J. 2022;24(2):38.
   PubMedGoogle Scholar
• Salem F, Johnson TN, Hodgkinson ABJ, et al., Does “birth” as an event impact maturation trajectory of renal clearance via glomerular filtration ? Reexamining data in preterm and full-term neonates by avoiding the creatinine bias. J Clin Pharmacol. 2021;61(2): 159–171.
   PubMedGoogle Scholar
• Krekels EH, van Ham S, Allegaert K, et al. Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants. Eur J Clin Pharmacol. 2015;71(9):1075–7082.
   PubMed Web of Science ®Google Scholar
• Abduljalil K, Jamei M, Rostami-Hodjegan A, et al., Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model. AAPS J. 2014;16(3): 568–576.
   PubMed Web of Science ®Google Scholar
• Verscheijden LFM, Koenderink JB, Johnson TN, et al. Physiology-based pharmacokinetic models for children: starting to reach maturation? Pharmacol Ther. 2020;211:107541.
   PubMed Web of Science ®Google Scholar
• Ward RM, Benjamin D, Barrett JS, et al. Safety, dosing and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates. Pediatr Res. 2017;81(5):692–711.
   PubMed Web of Science ®Google Scholar
• Johnson TN, Small BG, Berglund EG, et al., A best practice framework for applying physiologically-based pharmacokinetic modeling to pediatric drug development. CPT Pharmacometrics Syst Pharmacol. 2021;10(9): 967–972.
   PubMedGoogle Scholar
• Michelet R, van Bocxlaer J, Vermeulen A. PBPK in preterm and term neonates: a review. Curr Pharm Des. 2017;23(38):5943–5954.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Physiologically based pharmacokinetic analyses – format and content guidance for industry. [cited 2022 Apr 6]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/physiologically-based-pharmacokinetic-analyses-format-and-content-guidance-industry.
   Google Scholar
• European Medicines Agency. Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modeling and simulation. [cited 2022 Apr 6]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation_en.pdf.
   Google Scholar
• Smits A, De Cock P, Vermeulen A, et al., Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute. Expert Opin Drug Metab Toxicol. 2019;15(1): 24–34.
   Google Scholar
• Johnson TN, Small BG, Rowland Yeo K. Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations. CPT Pharmacometrics Syst Pharmacol. 2022;11(3):373–383.
   PubMedGoogle Scholar
• Abduljalil K, Pansari A, Gardner I, et al. Implementation of a physiologically based pharmacokinetic approach to predict theophylline pharmacokinetics using virtual non-pregnant, pregnant, fetal, breastfeeding and neonatal populations [abstract]. Clin Pharmacol Drug Dev. 2021;10(l1):74–75.
   Google Scholar
• Abduljalil K, Pan X, Pansari A, et al. Preterm physiologically based pharmacokinetic model. Part II: applications of the model to predict drug pharmacokinetics in the preterm population. Clin Pharmacokinet. 2020;59(4):501–518.
   PubMed Web of Science ®Google Scholar
• Abduljalil K, Pan X, Pansari A, et al. Authors’ reply to Völler et al: “comment on: preterm physiologically based pharmacokinetic model, part I and part II.” Clin Pharmacokinet. 2021;60(5):681–683.
   PubMedGoogle Scholar
• Brussee JM, Yu H, Krekels EHJ, et al. First-pass CYP3A-mediated metabolism of midazolam in the gut wall and liver in preterm neonates. CPT Pharmacometrics Syst Pharmacol. 2018;7(6):374–383.
   PubMedGoogle Scholar
• Castellan C, Kassaï B, Nguyen KC. Evaluation of a generic physiological based pharmacokinetic model for ciprofloxacin in term and preterm neonates [abstract]. Fundam Clin Pharmacol. 2011 25; 66;
   Google Scholar
• Claassen K, Thelen K, Coboeken K, et al., Development of a physiologically based pharmacokinetic model for preterm neonates: evaluation with in vivo data. Curr Pharm Des. 2015;21(39):5688–5698.
   PubMed Web of Science ®Google Scholar
• Fischer JW, Wu H, Cohen-Wolkowiez M, et al. Predicting the pharmacokinetics of piperacillin and tazobactam in preterm and term neonates using physiologically based pharmacokinetic modeling. Comput Toxicol. 2019;12:100104.
   Google Scholar
• Ganguly S, Edginton AN, Gerhart JG, et al. Physiologically based pharmacokinetic modeling of meropenem in preterm and term neonates. Clin Pharmacokinet. 2021;60(12):1591–1604.
   PubMedGoogle Scholar
• Gerhart JG, Watt KM, Edginton A, et al. Physiologically based pharmacokinetic modeling of fluconazole using plasma and cerebrospinal fluid samples from preterm and term infants. CPT Pharmacometrics Syst Pharmacol. 2019;8(7):500–510.
   PubMedGoogle Scholar
• Hahn D, Emoto C, Euteneuer JC, et al. Influence of OCT 1 ontogeny and genetic variation on morphine disposition in critically Ill neonates: lessons from pbpk modeling and clinical study. Clin Pharmacol Ther. 2019;105(3):761–768.
   PubMed Web of Science ®Google Scholar
• Johnson TN, Jamei M, Rowland-Yeo K. How does in vivo biliary elimination of drugs change with age ? Evidence from in vitro and clinical data using a systems pharmacology approach. Drug Metab Dispos. 2016;44(7):1090–1098.
   PubMed Web of Science ®Google Scholar
• Kovar L, Schräpel C, Selzer D, et al. Physiologically based pharmacokinetic (PBPK) modeling of buprenorphine in adults, children and preterm neonates. Pharmaceutics. 2020;12(6):578.
   Google Scholar
• Mahmood I, Tegenge MA. Spreadsheet-based minimal physiological models for the prediction of clearance of therapeutic proteins in pediatric patients. J Clin Pharmacol. 2021;61 Suppl 1(1):S108–S116.
   PubMedGoogle Scholar
• Mahmood I, Ahmad T, Mansoor N, et al. Prediction of clearance in neonates and infants (≤ 3 months of age) for drugs that are glucuronidated: a comparative study between allometric scaling and physiologically based pharmacokinetic modeling. J Clin Pharmacol. 2017;57(4):476–483.
   PubMed Web of Science ®Google Scholar
• Malik PRV, Edginton AN. Integration of ontogeny into a physiologically based pharmacokinetic model for monoclonal antibodies in premature infants. J Clin Pharmacol. 2020;60(4):466–476.
   PubMed Web of Science ®Google Scholar
• Mansoor N, Ahmad T, Alam Khan R, et al. Prediction of clearance and dose of midazolam in preterm and term neonates: a comparative study between allometric scaling and physiologically based pharmacokinetic modeling. Am J Ther. 2019;26(1):e32–e37.
   PubMedGoogle Scholar
• Michelet R, Van Bocxlaer J, Allegaert K, et al. The use of PBPK modeling across the pediatric age range using propofol as a case. J Pharmacokinet Pharmacodyn. 2018;45(6):765–785.
   PubMedGoogle Scholar
• Neeli H, Hanna N, Abduljalil K, et al. Application of physiologically based pharmacokinetic-pharmacodynamic modeling in preterm neonates to guide gentamicin dosing decisions and predict antibacterial effect. J Clin Pharmacol. 2021;61(10):1356–1365.
   PubMedGoogle Scholar
• Olafuyi O, Abbasi MY, Allegaert K. Physiologically based pharmacokinetic modelling of Acetaminophen in preterm neonates-The impact of metabolizing enzyme ontogeny and reduced cardiac output. Biopharm Drug Dispos. 2021;42(9):401–417.
   PubMedGoogle Scholar
• Pansari A, Abduljalil K, Johnson T. Predictive performance of a physiologically based pharmacokinetic model of caffeine in the preterm population [abstract]. Arch Dis Child. 2019;104(6):e1.
   PubMedGoogle Scholar
• Salerno SN, Edginton A, Gerhart JG, et al. Physiologically-based pharmacokinetic modeling characterizes the CYP3A-mediated drug-drug interaction between fluconazole and sildenafil in infants. Clin Pharmacol Ther. 2021;109(1):253–262.
   PubMedGoogle Scholar
• Wei L, Mansoor N, Khan RA, et al. WB-PBPK approach in predicting zidovudine pharmacokinetics in preterm neonates. Biopharm Drug Dispos. 2019;40(9):341–349.
   PubMedGoogle Scholar
• Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24(1):67–76.
   PubMed Web of Science ®Google Scholar
• Allegaert K, Cossey V, Langhendries JP, et al. Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. Biol Neonate. 2004;86(3):207–211.
   PubMedGoogle Scholar
• Abduljalil K, Jamei M, Johnson TN. Fetal physiologically based pharmacokinetic models: systems information on the growth and composition of fetal organs. Clin Pharmacokinet. 2019;58(2):235–262.
   PubMedGoogle Scholar
• Yang X, Wu H, Mehta D, et al. Ontogeny equations with probability distributions for anthropomorphic measurements in preterm and term neonates and infants for use in a PBPK model. Comp Toxicol. 2019; 11: 101–117.
   Google Scholar
• Bouazza N, Treluyer J-M, Foissac F, et al. Pharmacokinetics of intravenous paracetamol (Acetaminophen) and ductus arteriosus closure after premature birth. Clin Pharmacol Ther. 2021;110(4):1087–1095.
   PubMedGoogle Scholar
• Emoto C, Johnson TN, Neuhoff S, et al. PBPK model of morphine incorporating developmental changes in hepatic OCT1 and UGT2B7 proteins to explain the variability in clearances in neonates and small infants. CPT Pharmacometrics Syst Pharmacol. 2018;7(7):464–473.
   PubMedGoogle Scholar
• Matic M, de Wildt SN, Elens L, et al. SLC22A1/OCT1 genotype affects O-desmethyltramadol exposure in newborn infants. Ther Drug Monit. 2016;38(4):487–492.
   PubMedGoogle Scholar
• Smits A, Annaert P, Van Cruchten S, et al. A physiology-based pharmacokinetic framework to support drug development and dose precision during therapeutic hypothermia in neonates. Front Pharmacol. 2020;11:587.
   PubMedGoogle Scholar
• Johnson T. S10.2 - Pediatric PBPK: dealing with uncertain parameters and deciding on success criteria for predictability [abstract]. Drug Metab Pharmacokinet. 2020;35(l):S15–S16.
   Google Scholar
• Allegaert K, Smits A, van Donge T, et al. Renal precision medicine in neonates and acute kidney injury: how to convert a cloud of creatinine observations to support clinical decisions. Front Pediatr. 2020;8:366.
   PubMed Web of Science ®Google Scholar
• Deferm N, Annink KV, Faelens R, et al. Glomerular filtration rate in asphyxiated neonates under therapeutic whole-body hypothermia, quantified by mannitol clearance. Clin Pharmacokinet. 2021;60(7):897–906.
   PubMed Web of Science ®Google Scholar
• Cristea S, Allegaert K, Falcao AC, et al. Larger dose reductions of vancomycin required in neonates with patent ductus arteriosus receiving indomethacin versus ibuprofen. Antimicrob Agents Chemother. 2019;63(8):e00853–19.
   PubMedGoogle Scholar
• Allegaert K, Anderson BJ, van den Anker JN, et al. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther Drug Monit. 2007;29(3):284–291.
   PubMed Web of Science ®Google Scholar
• Boehm G, Teichmann B, Krumbiegel P. Hepatic biotransformation capacity in low-birth-weight infants as measured with the [15N]Methacetin urine test: influences of gestational age, postnatal age, and intrauterine growth retardation. Biol Neonate. 1995;68(1):19–25.
   PubMedGoogle Scholar
• Basu S, Lien YTK, Vozmediano V, et al. Physiologically based pharmacokinetic modeling of monoclonal antibodies in pediatric populations using PK-Sim. Front Pharmacol. 2020;11:868.
   PubMedGoogle Scholar
• Kimko H, Lee K. Improving realism in clinical trial simulations via real-world data. CPT Pharmacometrics Syst Pharmacol. 2017;6(11):727–729.
   PubMedGoogle Scholar
• Troutman JA, Sullivan MC, Carr GJ, et al. Development of growth equations from longitudinal studies of body weight and height in the full term and preterm neonate: from birth to four years postnatal age. Birth Defects Res. 2018;110(11):916–932.
   PubMedGoogle Scholar
• Allegaert K, van den Anker J. From immature pharmacotherapy towards pharmacotherapy of the immature. Semin Fetal Neonatal Med. 2022;27(2):101327.
   PubMedGoogle Scholar
• Allegaert K, van de Velde M, van den Anker J. Neonatal clinical pharmacology. Paediatr Anaesth. 2014;24(1):30–38.
   PubMed Web of Science ®Google Scholar